linjc16/ctgov huggingface dataset:
Clinical Study of mRNA Vaccine in Patients With Advanced Malignant Solid Tumors

Study Overview
=================
Brief Summary
-----------------
This study is an open, single arm, dose increasing study to evaluate the safety and efficacy of the combination of mRNA personalized tumor vaccine encoding neoantigen (hereinafter referred to as tumor vaccine) and Sintilimab injection (hereinafter referred to as Sintilimab) in the treatment of advanced malignant solid tumors.

Official Title
-----------------
Clinical Study on the Treatment of Advanced Malignant Solid Tumors With the Combination of mRNA

Conditions
-----------------
Advanced Malignant Solid Tumors

Intervention / Treatment
-----------------
* Biological: Neoantigen mRNA Personalised Cancer vaccine


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Are ≥18 years old, without limitation of sex at time of consent. Patients with malignant solid tumors confirmed by histopathology or cytology and having at least one measurable lesion. Fresh biopsy specimens can be provided for vaccine preparation. Patients with malignant solid tumors who develop secondary drug resistance after receiving PD-1/PD-L1 drug therapy, including but not limited to gastric cancer, esophageal cancer, and other gastrointestinal tumors of MSI-H Exclusion Criteria: It is known that it is allergic to any tumor vaccine and Sintilimab preparations; Or have experienced severe allergic reactions to other monoclonal antibodies in the past; The predicted number of new antigens is less than 10; Those who are pregnant or breastfeeding; Those with an expected survival period of less than 3 months;

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Intervention Model: Single Group Assignment
Interventional Model Description: PD-1/PD-L1 drug therapy benefits patients with secondary drug-resistant malignant solid tumors, including but not limited to gastric cancer, esophageal cancer, and other gastrointestinal tumors of MSI-H.
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: single arm<br>Neoantigen mRNA Personalised Cancer in combination with Stintilimab Injection. Participants will receive a total of 9 cycles of PCV every 21 days | Biological: Neoantigen mRNA Personalised Cancer vaccine<br>* Drug: Neoantigen mRNA Personalised Cancer vaccine in combination with Stintilimab Injection Subcutaneous Injection<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| progression-free survival (PFS) |  | Time Frame: from enrolling to patients disease progression，assessed up to 24 months |
Sleep After Pediatric Critical Illness

Study Overview
=================
Brief Summary
-----------------
This study tests a pilot educational sleep intervention for children after critical care hospitalization.

Detailed Description
-----------------
The investigators are conducting a before-after study evaluating an educational intervention delivered during hospitalization on sleep outcomes 1month after critical care hospitalization for children aged 6 to 18 years.

Official Title
-----------------
Sleep Disturbances for Children After Critical Care: Pilot Sleep Education Intervention

Conditions
-----------------
Pediatric, Critical Illness, Sleep Disturbance

Intervention / Treatment
-----------------
* Behavioral: Sleep education


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Age 6 years to 18 years inclusive Inpatient consult to Pediatric Critical Care and Neurotrauma Recovery Program Exclusion Criteria: Abusive trauma Child protective services custody Prisoners Pregnancy Non-English speaking caregivers

Ages Eligible for Study
-----------------
Minimum Age: 6 Years
Maximum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Supportive Care
Allocation: Non-Randomized
Intervention Model: Sequential Assignment
Interventional Model Description: Before-after
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| No Intervention: Before- standard care<br> | |
| Other: After- intervention<br>Patients studied in this arm receive the new educational intervention delivered in conjunction with standard care | Behavioral: Sleep education<br>* Participants receive a handout about age appropriate sleep goals and tips for improving sleep. The handout also contains links to educational videos about sleep hygiene and the importance of sleep to healing after illness. The handout is reviewed with a clinician at bedside prior to hospital discharge.<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Sleep Disturbances Scale for Children | 26-item parent report sleep measure; generates total T-score and 6 subscale T-scores (range 0-100, M 50, SD 10) | 1-month | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Pediatric Quality of Life Inventory Scale (PedsQL) | Parent rated quality of life measure, age based; Generates total score 0-100 | 1-month |
Comparison Of Effects of MRP Vs NDT For Balance and Gait in Chronic Ischemic Stroke Patients RCT

Study Overview
=================
Brief Summary
-----------------
To determine the comparison between effects of Motor Relearning Program (MRP) and Neuro-Development Treatment (NDT) on balance and gait in chronic ischemic stroke patients.

Official Title
-----------------
Comparison Of Effects of Motor Relearning Program (MRP) Versus Neuro Development Treatment (NDT) For Balance and Gait in Chronic Ischemic Stroke Patients: A Randomized Clinical Trial

Conditions
-----------------
Stroke

Intervention / Treatment
-----------------
* Diagnostic Test: Motor Relearning Program (MRP)
* Diagnostic Test: Neuro Development Treatment (NDT)


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Chronic ischemic stroke Patients more than 6 months. (55) Patient with good cognitive status minimum 20 or greater out of 30 in Mini mental state examinations.(56) Age between 45-65 years.(57) Patient with limb spasticity equal to 2 or less than 2 on Modified Ashworth scale.(56) Both male and female patients.(58) Exclusion Criteria: History of neurologic disease(59, 60) History of lower limb fracture.(61) History of spinal cord fracture.(61) Patient with skin discoloration, skin ulcers and skin allergy.(62) Patients with a history of the recurrent stroke. (63) Patients with any peripheral vascular disease.(60)

Ages Eligible for Study
-----------------
Minimum Age: 45 Years
Maximum Age: 65 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Health Services Research
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Motor Relearning Program (MRP)<br> | Diagnostic Test: Motor Relearning Program (MRP)<br>* MRP technique with a conventional physiotherapy treatment. Conventional physiotherapy treatment will help to reduce the functional impairments in chronic ischemic stroke<br>|
| Experimental: Neuro Development Treatment (NDT)<br> | Diagnostic Test: Neuro Development Treatment (NDT)<br>* Neuro-Development Treatment NDT as well as conventional treatment. Conventional physiotherapy treatment will help to reduce the functional impairments in chronic ischemic stroke patients<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Effects of Motor Relearning Program Techinique, Neuro Development Treatment Techinique |  | 6 Months |
Defining, Evaluating, and Sharing Methodologies for Quality Control in Diagnostic Imaging

Study Overview
=================
Brief Summary
-----------------
The purpose of the study is to validate a radiological quality control (QC) system on the performance of diagnostic imaging. Patient images, previously anonymized by each radiologic diagnostic structures (SDR), will be sent to the QC service, which will blindly submit the images for evaluation external peer review by experts in the field. Through the blinded approach, the information obtained from the QC will allow the SDR to know its own performance analytics, but not those of other SDRs using the service, and to a centralized system to have an anonymized estimate of the quality of performance delivered. Finally, the analyzed data will provide not only a mere count, but will allow to reduce and prevent errors in the appropriateness, execution, reporting and diagnostic content of the examinations

Official Title
-----------------
Defining, Evaluating, and Sharing Methodologies for Quality Control in Diagnostic Imaging

Conditions
-----------------
Subjects Undergoing Diagnostic Imaging Tests

Intervention / Treatment
-----------------
* Other: imaging tests


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Diagnostic examinations related to imaging modalities (RX, CT, MR, PET, SPECT...), agreed with SDRs, of body districts on which diagnostic images are available in DICOM format, medical history data and clinical question, report Exclusion Criteria: Incompleteness of data for the purpose of the review process
Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Intervention/Treatment |
| --- |
|Other: imaging tests|X-ray radiography (RX); computer tomography (CT); magnetic resonance (MR); positron emission tomography (PET); single photon emission computed tomography (SPECT)|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Definition and implementation of diagnostic image quality control procedures for the purpose of purposes of monitoring the accuracy and appropriateness of the service provided by SDRs | Definition of a survey for evaluation of diagnostic procedures; Definition of a panel of experts; Optimization of radiological quality control workflow; Identification of elements for workflow automation; Definition of feedback strategies for the improvement of procedures diagnostics | 1-36 months |
Determining Developmental and Clinical Markers Affecting Urinary Function of Children With Spinal Dysraphism

Study Overview
=================
Brief Summary
-----------------
To identify developmental and clinical biomarkers that affect urinary incontinence at the ages of 5, 7, and 10 according to different neuro-urological clinical factors.

Detailed Description
-----------------
This retrospective observational cohort study aims to identify developmental and clinical biomarkers that affect urinary incontinence at the ages of 5, 7, and 10 according to the types of spinal dysraphism, conus medullaris location, and urodynamics test results.

Official Title
-----------------
Determining Developmental and Clinical Markers Affecting Urinary Function of Children With Spinal Dysraphism: A Multicenter, Retrospective Cohort

Conditions
-----------------
Spinal Dysraphism

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: - Those who received spinal dysraphism diagnosis (ICD Code: Q05.1-05.9) and have been following up and receiving treatments due to neurogenic bladder. Exclusion Criteria: - As the study is a retrospective study, there is no exclusion criteria.

Ages Eligible for Study
-----------------
Maximum Age: 10 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Achieving full continence at age 5 | Achieving full urinary and fecal continence at age 5 | Age 5 | 
| Achieving full continence at age 7 | Achieving full urinary and fecal continence at age 7. | Age 7 | 
| Achieving full continence at age 10 | Achieving full urinary and fecal continence at age 10 | Age 10 | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Spina Bifida, Neurogenic Bladder, Neurogenic Detrusor Overactivity, Detrusor Overactivity, Incontinence
Telehealth Treatment for Alcohol Use Disorder

Study Overview
=================
Brief Summary
-----------------
Participants with alcohol use disorder will be randomly assigned to either the Ria Treatment Platform or a waitlist control. The Ria Treatment Platform is a telehealth approach that incorporates medical assessment, medications for alcohol use disorder, individual and group coaching, educational video modules, and a Bluetooth-enabled breathalyzer. Patients are followed for three months during which data are collected, including measures of alcohol consumption and its consequences.

Official Title
-----------------
A Telehealth Intervention to Increase Screening and Treatment for Alcohol Use Disorder

Conditions
-----------------
Alcoholism, Alcohol Use Disorder, Alcohol Dependence

Intervention / Treatment
-----------------
* Combination Product: Ria Treatment Platform


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: alcohol use disorder Exclusion Criteria: inability to provide informed consent

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Interventional Model Description: participants will be randomly assigned in a 1:1 to the Ria Treatment Platform or a waitlist control condition
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Ria Treatment Platfrom<br>The Ria Treatment Platform is a telehealth approach that includes medical assessment, prescription of clinically appropriate medications for alcohol use disorder, individual and group coaching, educational video modules, and monitoring of breath alcohol concentrations through a Bluetooth-enabled breathalyzer. | Combination Product: Ria Treatment Platform<br>* combined medication, coaching, education, and monitoring<br>|
| No Intervention: waitlist control<br>Patients in this arm will not be provided treatment during the study period. | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| percent of subjects without heavy drinking | percent of subjects without heavy drinking per timeline follow-back | last four weeks |
Evaluation of Immersion in Virtual Reality in the Management of Anxiety, Then Pain, of Patients in Interventional Imaging.

Study Overview
=================
Brief Summary
-----------------
Investigators propose to use static VR scenarios, adapted to the patient's preferences (sea, mountain, countryside…) to immerse them in an emotionally positive environment. The objective is to reduce the anxiety and pain associated with IR acts in the operating room. Hypothesis tested: The use of the 3D immersion of an oculus rift DK2 virtual reality headset during an interventional radiology intervention would reduce the anxiety felt by patients by 25%, evaluated by the STAI YB scale. The correlation between the STAI YB and the APAIS and HAD scales will also be tested.

Official Title
-----------------
Evaluation of Immersion in Virtual Reality in the Management of Anxiety, Then Pain, of Patients in Interventional Imaging.

Conditions
-----------------
Interventional Imaging

Intervention / Treatment
-----------------
* Other: Virtual Reality


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patients (18-80 years old) with an indication for performing one of the following interventional radiology procedures, according to HAS recommendations: Liver biopsy puncture, embolization of varicoceles, embolization of pelvic varices, embolization of uterine fibroids, Hepatic arterial chemoembolization for hepatocellular carcinoma, radioembolization. Exclusion Criteria: Pregnant or breastfeeding women. Minor or age > 80 years. People suffering from psychiatric pathologies, chronic depressive syndrome or chronic anxiety disorder. People with a high risk of motion sickness during virtual reality immersion (MMSQ and VIMSSQ > 80th percentile).

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 80 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Basic Science
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Virtual Reality<br> | Other: Virtual Reality<br>* Immersion in Virtual Reality<br>|
| No Intervention: standard care<br> | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| anxiety measured with STAI Y-B | For the main objective, the STAI Y-B will be used to assess reactive anxiety as close as possible to the interventional gesture, i.e. just after it. | once (as close as possible to the interventional gesture, i.e. just after it.) |
Adding Desmopressin to Tamsulosin for Treatment of BPH

Study Overview
=================
Brief Summary
-----------------
In this study investigators will add desmopressin for treatment of patients with benign prostatic hyperplasia and nocturnal polyurea

Detailed Description
-----------------
Investigators will give a group of patients tamsulosin and desmopressin and the other group will take tamsulosin and placepo and compare the outcome regarding symptoms of being prostatic hyperplasia especially nocturia and the effect on nocturnal polyurea in patients

Official Title
-----------------
Outcome of Adding Desmopressin to Tamsulosin for Treatment of Nocturnal Polyurea in Patients With Benign Prostatic Obstruction

Conditions
-----------------
Nocturnal Polyurea in Patients With BPH

Intervention / Treatment
-----------------
* Drug: Desmopressin Acetate
* Drug: Placebo


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Men with BPH Age more than 50years Patients with nocturia (2voids per night or More) Patients with nocturnal polyurea (urine volume More than 33%of urine allover the day) IPSS more than 12 Obstructed flow curve Post voiding residual less than 150 Exclusion Criteria: men with BPH with : Acute urine retention Neurogenic bladder dysfunction Cardiovascular disease Hyponatremia Urethral stricture Bladder calculi Prostate cancer

Ages Eligible for Study
-----------------
Minimum Age: 50 Years
Maximum Age: 80 Years

Sexes Eligible for Study
-----------------
Male

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Active Comparator: Desmopressin arm<br>This arm will receive tamsulosin and desmopressin | Drug: Desmopressin Acetate<br>* This arm will receive tamsulosin and desmopressin acetate daily a<br>|
| Placebo Comparator: Placebo arm<br>This arm will receive tamsulosin and placepo | Drug: Placebo<br>* This arm will receive tamsulosin and placebo<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Change of symptoms and nocturia disappears or improve | Investigators will compare symptoms in the pretreatment period and follow up symptoms following treatment and record the outcome | Follow up for 6 months |
Single-stage Correction of Acute Angle Coxa Vara

Study Overview
=================
Brief Summary
-----------------
Correction of sever degree of coxa vara in single-stage correction.

Detailed Description
-----------------
The technique described in this article illustrates how to fully correct acute angle developmental coxa vara (neck shaft angle 30 degrees) to obtain better radiological and functional outcomes. GT transfer Subtroch. valgus osteotomy

Official Title
-----------------
Single-stage Correction of Acute Angle Coxa Vara

Conditions
-----------------
Coxa Vara

Intervention / Treatment
-----------------
* Procedure: greater trochanter transfer, subtrochanteric valgus osteotomy


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: acute coxa vara Exclusion Criteria: osteopenic oI

Ages Eligible for Study
-----------------
Minimum Age: 3 Years
Maximum Age: 40 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Intervention Model: Single Group Assignment
Interventional Model Description: greater trochanter transfer and subtrochanteric valgus osteotomy
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: greater trochanter transfer and subtrochanteric valgus osteotomy<br>greater trochanter transfer, subtrochanteric valgus osteotomy fixation by Wagner & TB and Locked plate | Procedure: greater trochanter transfer, subtrochanteric valgus osteotomy<br>* greater trochanter transfer, subtrochanteric valgus osteotomy fixation by wagner TB and locked plate<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| modified McKay's criteria | Hip function score Excelent Good Fair Poor | 1 year | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
greater trochanter transfer, Wagner technique, subtrochanteric valgus osteotomy, tension band wiring., coxa vara, proximal femur osteotomy